{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:15:02Z","timestamp":1792664102746,"version":"4.5.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T00:00:00Z","timestamp":1502150400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2017,8,8]]},"DOI":"10.3233\/jpd-171134","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T11:39:24Z","timestamp":1501846764000},"page":"511-522","source":"Crossref","is-referenced-by-count":44,"title":["ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson\u2019s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study"],"prefix":"10.1177","volume":"7","author":[{"given":"Robert A.","family":"Hauser","sequence":"first","affiliation":[{"name":"University of South Florida, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Kansas City, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Tanner","sequence":"additional","affiliation":[{"name":"University of California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Oertel","sequence":"additional","affiliation":[{"name":"Philipps University, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Parkinson\u2019s Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed","family":"Johnson","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc., Emeryville, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Felt","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc., Emeryville, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jean","family":"Stempien","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc., Emeryville, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-171134_ref1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: A review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"10.3233\/JPD-171134_ref2","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00018-015-2101-1","article-title":"Current disease modifying approaches to treat Parkinson\u2019s disease","volume":"73","author":"Lindholm","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.3233\/JPD-171134_ref3","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1007\/s00415-010-5741-y","article-title":"A brief history of levodopa","volume":"257","author":"Hornykiewicz","year":"2010","journal-title":"J Neurol"},{"key":"10.3233\/JPD-171134_ref4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","article-title":"The scientific and clinical basis for the treatment of Parkinson disease (2009)","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JPD-171134_ref5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1741-7015-11-76","article-title":"Drug-induced dyskinesia in Parkinson\u2019s disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?","volume":"11","author":"Daneault","year":"2013","journal-title":"BMC Med"},{"key":"10.3233\/JPD-171134_ref6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-171134_ref7","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00702-015-1396-2","article-title":"Falls inambulatory non-demented patients with Parkinson\u2019s disease","volume":"122","author":"Rascol","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"key":"10.3233\/JPD-171134_ref8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jns.2012.05.029","article-title":"Treatment patterns and associated costs with Parkinson\u2019s disease levodopa induced dyskinesia","volume":"319","author":"Suh","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.3233\/JPD-171134_ref9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson\u2019s disease on the quality of life","volume":"20","author":"Chapuis","year":"2005","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-171134_ref10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.parkreldis.2014.06.001","article-title":"Quality of life in Parkinson\u2019s disease patients with motor fluctuations and dyskinesias in five European countries","volume":"20","author":"Hechtner","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 3","key":"10.3233\/JPD-171134_ref11","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.23829","article-title":"The Movement Disorder Society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson\u2019s disease","volume":"26","author":"Fox","year":"2011","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-171134_ref12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"key":"10.3233\/JPD-171134_ref13","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.3233\/JPD-171134_ref14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(70)91211-0","article-title":"Amantadine dosage in treatment of Parkinson\u2019s disease","volume":"1","author":"Parkes","year":"1970","journal-title":"Lancet"},{"key":"10.3233\/JPD-171134_ref15","doi-asserted-by":"crossref","unstructured":"Pahwa R , Tanner CM , Hauser RA , Isaacson SH , Nausieda PA , Truong DD , Agarwal P , Hull KL , Lyons KE , Johnson R , & Stempien MJ (2017) ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson Disease (EASE LID Study): A randomized clinical trial. JAMA Neurol, doi: 10.1001\/jamaneurol.2017.0943. [Epub ahead of print].","DOI":"10.1001\/jamaneurol.2017.0943"},{"key":"10.3233\/JPD-171134_ref16","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/mds.26159","article-title":"Amantadine extended release for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASED Study)","volume":"30","author":"Pahwa","year":"2015","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-171134_ref17","unstructured":"Oertel W , Eggert K , Pahwa R , Tanner CM , Hauser RA , Trenkwalder C , Ehret R , Azulay JP , Isaacson S , Felt L , & Stempien MJ (2017) ADS-5102 for the treatment of levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3 study). Mov Disord, in press."},{"key":"#cr-split#-10.3233\/JPD-171134_ref18.1","unstructured":"Hauser RA , Pahwa R , Tanner CM , Oertel W , Johnson R , Felt L , & Stempien MJ (2017) Update to Interim Results of a Long-term Open-label Safety Study of ADS-5102 (amantadine hydrochloride) Extended-Release Capsules for Treatment of Levodopa-Induced Dyskinesia (LID) (EASE LID 2 Study). Poster presented at: 1st Pan American Parkinson's Disease and Movement Disorders Congress"},{"key":"#cr-split#-10.3233\/JPD-171134_ref18.2","unstructured":"February 24-26, 2017, Poster, 92-Miami, FL."},{"key":"10.3233\/JPD-171134_ref19","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.parkreldis.2014.06.023","article-title":"Natural history of falls in a population-based cohort of patients with Parkinson\u2019s disease: An 8-year prospective study","volume":"20","author":"Hiorth","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-171134_ref20","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/mds.22130","article-title":"Suicidal and death ideation in Parkinson\u2019s disease","volume":"23","author":"Nazem","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-171134_ref21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-016-0600-5","article-title":"Psychosis in Parkinson\u2019s disease: Epidemiology, pathophysiology, and management","volume":"76","author":"Chang","year":"2016","journal-title":"Drugs"},{"key":"10.3233\/JPD-171134_ref22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/pgmj.2006.054759","article-title":"Levodopa-induced dyskinesia in Parkinson\u2019s disease: Clinical features, pathogenesis, prevention and treatment","volume":"83","author":"Thanvi","year":"2007","journal-title":"Postgrad Med J"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-171134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:45:52Z","timestamp":1777610752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-171134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,8]]},"references-count":23,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jpd-171134","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,8]]}}}